McKesson Corporation
MCK Healthcare Medical - Distribution NYSE
$808.62
$-5.56 (-0.68%)
Open: $812.49 | High: $818.92 | Low: $806.29 | Prev Close: $814.18
Market Cap: $101.08B
Volume: 447K | Avg: 743K
Last updated: December 05, 2025 at 10:05 PMInvestment Rating
Sell
Overall Score: 40/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 455
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 25.29 |
| P/B Ratio | -51.35 |
| P/S Ratio | 0.27 |
| EPS | $31.97 |
| Beta | 0.39 |
| Shares Outstanding | 125.00M |
| 52-Week High | $895.58 |
| 52-Week Low | $558.13 |
| SMA 50 | $811.37 |
| SMA 200 | $722.22 |
| Dividend Yield | 0.41% |
| Annual Dividend | $3.28 |
| Next Earnings | February 04, 2026 09:00 PM ET |
Financial Ratios
| Gross Margin | 3.3% |
| Operating Margin | 1.1% |
| Net Margin | 0.8% |
| ROE | -124.8% |
| ROA | 3.9% |
| Debt/Equity | -5.05 |
| Current Ratio | 0.88 |
| Quick Ratio | 0.49 |
Balance Sheet
| Total Assets | $75.14B |
| Total Liabilities | $76.83B |
| Total Equity | $-2,074,000,000 |
| Cash | $5.69B |
| Total Debt | $7.39B |
| Net Debt | $1.70B |
Income Statement
| Revenue | $359.05B |
| Gross Profit | $12.48B |
| Operating Income | $4.37B |
| Net Income | $3.29B |
| EBITDA | $5.25B |
| Revenue/Share | $3023.18 |
Cash Flow
| Operating CF | $6.08B |
| CapEx | $859.00M |
| Free Cash Flow | $5.23B |
| Book Value/Share | $-6.91 |
| Tangible Book/Share | $-132.11 |
| Equity/Share | $-15.75 |
Technical Indicators
| RSI (14) | 40.38 Neutral |
| MACD |
6.68
Signal: 15.99
|
| Volatility | 24.38% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +34.16% |
| Sharpe Ratio | 1.5 Good |
| Volatility (Ann.) | 24.25% Moderate |
| MCK (1Y) | +34.16% |
| S&P 500 (1Y) | +11.86% |
| Alpha (Excess Return) | +22.29% |
Sector Comparison (Healthcare)
| Metric | MCK | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 25.29 | 31.3 | 48% |
| P/B Ratio | -51.35 | 0.31 | 3% |
| ROE (%) | -124.79% | 12.08% | 5% |
| Net Margin (%) | 0.84% | 10.20% | 13% |
| Stock Score | 455 | 505.0 | 22% |
| 1Y Return (%) | +34.16% | +3.91% | 90% |
Historical Price Analysis (Last 200 Days)
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCK | $808.62 | $837.45 | $853.81 | $854.95 | $811.37 | $722.22 | 40.38 | 6.68 | 24.38% | 880965 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the MCK stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| MCK | McKesson Corporation (MCK) Presents at Evercore 8th Annual Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| MCK | Brandes Investment Partners LP Sells 151,828 Shares of McKesson Corporation $MCK | Neutral | defenseworld.net | Read More |
| MCK | McKesson's Advancing Community Oncology Report Charts a New Era of Innovation for Biopharma and Community Care | Neutral | businesswire.com | Read More |
| MCK | Financial Survey: McKesson (NYSE:MCK) vs. Align Technology (NASDAQ:ALGN) | Neutral | defenseworld.net | Read More |
| MCK | Here's Why McKesson (MCK) is a Strong Growth Stock | Positive | zacks.com | Read More |
Company Information
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
| CEO | Brian S. Tyler |
| Employees | 44000 |
| Country | US |
| IPO Date | 1994-11-10 |
| Exchange | NYSE |
| Website | https://www.mckesson.com |
| Sector | Healthcare |
| Industry | Medical - Distribution |
Similar Stocks (Healthcare - Medical - Distribution)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category